What does the evidence show about 9-Me-BC (9-methyl-β-carboline)'s effects?

Read Off Label rates the evidence for 9-Me-BC (9-methyl-β-carboline) as Preclinical only and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Obscure research chemical with intriguing but exclusively preclinical evidence.

What safety findings are reported for 9-Me-BC (9-methyl-β-carboline)?

9-Me-BC (9-methyl-β-carboline) has a unclear risk profile in the database. Unknown (no human safety data; theoretical MAOI/serotonin syndrome risk; broader β-carboline class includes co-mutagens and parkinsonian-neurotoxin precursors via N-methyl-β-carbolinium bioactivation — a specific concern for chronic dosing) Legal status: Research chem.

Rankings / Cognitive

9-Me-BC (9-methyl-β-carboline)

Cognitive · Beta-carboline / neurotrophic

Tier D

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

dopaminebdnfmao-inhibitorneurogenesisresearch-only

3.3 / 10

Tier D

Ev 2 Bn 5 Sf 4

Bottom line

Read Off Label grades 9-Me-BC (9-methyl-β-carboline) as D (3.3/10) based on preclinical only evidence, unclear benefit magnitude, and a unclear-risk safety profile.

Obscure research chemical with intriguing but exclusively preclinical evidence.

Studied, labeled, or reported-use context: No established human dosing — Research chem; not individualized guidance.

Frontier potential — editorial judgment, not evidence

This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.

4/10

Mechanistic story only Preclinical

What the ceiling rests on

Reported dopaminergic and neurotrophic effects in animal models, including dopamine-neuron protection and increases in dendritic complexity — an unusual combination of stimulant-like and neurotrophic activity in one molecule.

Why it may not get there

Rodent work only, from a small number of groups. Beta-carbolines are a chemically promiscuous class with MAO-inhibitory activity and interaction potential, and no human pharmacokinetic or safety data exist. Sold as a research chemical with no oversight of identity or purity.

What would change this Independent replication plus a first human pharmacokinetic study.

What the evidence says

Obscure research chemical with intriguing but exclusively preclinical evidence. The Dresden group (Polanski; Reichmann; Gille) and Berlin Charité collaborators (Hamann; Wernicke; Bringmann; Rommelspacher) demonstrated dopaminergic neuroprotection in mouse Parkinson's models; Ostrowska 2020 (PMC8592951) showed doubled BDNF and ~3.2x Artemin expression in astrocyte culture plus MAO-A/B inhibition (IC50 ~1 μM / ~15.5 μM); Hamann 2012 (PMID 22380576) showed cognitive enhancement with hippocampal dendritic/synaptic proliferation. No human trials of any kind. Sold in gray-market nootropic shops with extravagant claims. Two safety caveats biohacker forums minimize: (1) the broader β-carboline class includes compounds that are co-mutagenic with aromatic amines, and (2) β-carbolines can bioactivate to N-methyl-β-carbolinium cations — structurally analogous to MPP+ (the active parkinsonian neurotoxin metabolized from MPTP). The latter is a theoretical chronic-use concern that has NOT been specifically ruled out for 9-Me-BC. Human safety data are absent.

Mechanism

Mixed MAOI (MAO-A IC50 ~1 μM; MAO-B IC50 ~15.5 μM); proposed to stimulate dopaminergic neurogenesis and neuroprotection via BDNF and GDNF upregulation; dendritic and synaptic proliferation in rat hippocampus; PI3K/Akt anti-neuroinflammatory signaling in preclinical models; endogenous β-carboline also present in coffee; meats; and tobacco smoke

Studied, labeled, or reported dose & route

No established human dosing

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about 9-Me-BC (9-methyl-β-carboline)'s effects?: Read Off Label rates the evidence for 9-Me-BC (9-methyl-β-carboline) as Preclinical only and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Obscure research chemical with intriguing but exclusively preclinical evidence.
What safety findings are reported for 9-Me-BC (9-methyl-β-carboline)?: 9-Me-BC (9-methyl-β-carboline) has a unclear risk profile in the database. Unknown (no human safety data; theoretical MAOI/serotonin syndrome risk; broader β-carboline class includes co-mutagens and parkinsonian-neurotoxin precursors via N-methyl-β-carbolinium bioactivation — a specific concern for chronic dosing) Legal status: Research chem.
What doses or routes are reported for 9-Me-BC (9-methyl-β-carboline)?: No established human dosing This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does 9-Me-BC (9-methyl-β-carboline) work?: Mixed MAOI (MAO-A IC50 ~1 μM; MAO-B IC50 ~15.5 μM); proposed to stimulate dopaminergic neurogenesis and neuroprotection via BDNF and GDNF upregulation; dendritic and synaptic proliferation in rat hippocampus; PI3K/Akt anti-neuroinflammatory signaling in preclinical models; endogenous β-carboline also present in coffee; meats; and tobacco smoke

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.